Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups from the ε-N-acetyl lysine residues on histone and non-histone proteins. This enzymatic activity leads to chromatin condensation and transcriptional repression, playing a central role in the regulation of gene expression, cell cycle progression, development, and disease states such as cancer. There are 18 known HDAC enzymes divided into four classes based on sequence homology and cofactor dependency: Class I (HDAC1, HDAC2, HDAC3, HDAC8), Class II (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10), Class III (SIRT1–SIRT7), and Class IV (HDAC11).
HDAC inhibitors bind to the active site of HDAC enzymes, preventing the removal of acetyl groups from histone and non-histone proteins. This leads to increased acetylation, chromatin relaxation, and altered gene expression, often resulting in cell cycle arrest or apoptosis, particularly in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone Deacetylase.